Innovent Biologics / 信达生物
Innovent Biologics / 信达生物 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 through the episode’s discussion of dual-payload ADCs. The source says related presentations from WuXi and Innovent showed this direction, where ADC design moves from one antibody plus one payload toward bispecific and dual-payload combinations.
The source treats Innovent as a signal of Chinese companies exploring harder ADC engineering, not as a settled proof that the format will become clinically or commercially dominant.
156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 shifts Innovent’s source role from ADC exploration to PD-1/IL-2 Bispecific and global cooperation. The episode says its Takeda deal uses global cost sharing and profit sharing, making Innovent a case for moving beyond simple license-out into co-development.
Connections
- Dual-Payload ADC and ADC Engineering Optimization - technical context.
- China Biotech Asset Repricing - broader Chinese biotech asset interest.
- Finite-Game Biotech Competition - mature-platform competition context.
- PD-1/IL-2 Bispecific, Takeda Pharmaceutical / 武田制药, and Platform-Level Biotech BD - episode 156 cooperation and mechanism-design context.